Background: It is believed that vitiligo has an impact on the overall patient quality of life (QoL). Objective: To estimate QoL in a fairly large sample of Italian vitiligo patients by using the Dermatology Life Quality Index (DLQI) questionnaire. Methods: One hundred and sixty-one vitiligo patients referred to 9 dermatological centers were offered to participate by filling in the Italian version of the DLQI questionnaire. Results: The mean total DLQI score was 4.3 (SD ±4.9; range: 0-22). In multivariate analysis, DLQI >5 was associated with female gender, stability of the disease over time and involvement of the face at disease onset. Conclusions: The impairment of QoL is overall limited in Italian vitiligo patients, especially if it is compared with results from other available studies. This could be due to cultural and ethnic characteristics of the sample.

Keywords:
Vitiligo, Quality of life, Dermatology Life Quality Index, Italian vitiligo patients
1.
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V: Vitiligo: a comprehensive overview. J Am Acad Dermatol 2011;65:473-491.
2.
Handa S, Kaur I: Vitiligo: clinical findings in 1,436 patients. J Dermatol 1999;26:653-657.
3.
Howitz J, Brodthage H, Schwartz M, Thomsen K: Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977;113:47-52.
4.
Naldi L, Colombo P, Placchesi EB, Piccitto R, Chatenoud L, La Vecchia C; PraKtis Study Centers: Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004;208:38-42.
5.
Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L: The ‘EpiEnlist' project: a dermo-epidemiologic study on a representative sample of young Italian males. Prevalence of selected pigmentary lesions. J Eur Acad Dermatol Venereol 2007;21:1091-1096.
6.
Porter JR, Beuf AH, Nordlund JJ, Lerner AB: Psychological reaction to chronic skin disorders. A study of patients with vitiligo. Gen Hosp Psychiatry 1979;1:73-77.
7.
Kent G, Al-Abadie M: Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996;21:330-333.
8.
Porter JR, Beuf HA, Lerner AB, Nordlund JJ: Psychosocial effect of vitiligo: a comparison of vitiligo patients with normal subjects, with psoriasis patients with other pigmentary disorders. J Am Acad Dermatol 1986;15:220-224.
9.
Parsad D, Dogra S, Kanwar AJ: Quality of life in patients with vitiligo. Health Qual Life Outcomes 2003;1:58.
10.
Porter JR, Beuf AH, Lerner AB, Nordlund JJ: The effect of vitiligo on sexual relationships. J Am Acad Dermatol 1990;22:221-222.
11.
Ongenae K, van Geel N, De Schepper S, Naeyaert JM: Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005;152:1165-1172.
12.
Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B: Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003;148:373-374.
13.
Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY: DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2004;4:8.
14.
Mechri A, Amri M, Douarika AA, Ali Hichem BH, Zouari B, Zili J: Psychiatric morbidity and quality of life in vitiligo: a case controlled study. Tunis Med 2006;84:632-635.
15.
Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM: Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005;210:279-285.
16.
Van Geel N, Ongenae K, Vander Heghen Y, Vervaet C, Naeyaert JM: Subjective and objective evaluation of noncultured epidermal cellular grafting for repigmenting vitiligo. Dermatology 2006;213:23-29.
17.
Belhadjali H, Amri M, Mecheri A, Doarika A, Khorchani H, Youssef M, Gaha L, Zili J: Vitiligo and quality of life: a case-control study. Ann Dermatol Venereol 2007;134:233-236.
18.
Al Robaee AA: Assessment of quality of life in Saudi patients with vitiligo in a medical school in Qassim province, Saudi Arabia. Saudi Med J 2007;28:1414-1417.
19.
Dolatshahi M, Ghazi P, Feizy V, Hemami MR: Life quality assessment among patients with vitiligo: comparison of married and single patients in Iran. Indian J Dermatol Venereol Leprol 2008;74:700.
20.
Kostopoulou P, Jouary T, Quintard B, Ezzedine K, Marques S, Boutchnei S, Taieb A: Objective vs subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. Br J Dermatol 2009;161:128-133.
21.
Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M: Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 2009;161:134-139.
22.
Mashayekhi V, Javidi Z, Kiafar B, Manteghi AA, Saadatian V, Esmaeili HA, Hosseinalizadeh S: Quality of life in patients with vitiligo: a descriptive study on 83 patients attending a PUVA therapy unit in Imam Reza Hospital, Mashad. Indian J Dermatol Venereol Leprol 2010;76:592.
23.
Wang KY, Wang KH, Zhang ZP: Health-related quality of life and marital quality of vitiligo patients in China. J Eur Acad Dermatol Venereol 2011;25:429-435.
24.
Chan MF, Chua TL, Goh BK, Aw CWD, Thng TGS, Lee SM: Investigating factors associated with depression of vitiligo patients in Singapore. J Clin Nurs 2011;21:1614-1621.
25.
Ingordo V, Cazzaniga S, Gentile C, Iannazzone SS, Cusano F, Naldi L: Dermatology Life Quality Index score in vitiligo patients: a pilot study among young Italian males. G Ital Dermatol Venereol 2012;147:83-90.
26.
Wong S, Bao MBBCH, Baba R: Quality of life among Malaysian patients with vitiligo. Int J Dermatol 2012;51:156-161.
27.
Silverberg JI, Silverberg NB: Association between vitiligo extent and distribution and quality-of-life. JAMA Dermatol 2013;149:159-164.
28.
Kiprono S, Chaula B, Makwaya C, Naafs B, Masenga J: Quality of life of patients with vitiligo attending the Regional Dermatology Training Center in Northern Tanzania. Int J Dermatol 2013;52:191-194.
29.
Karelson M, Silm H, Kingo K: Quality of life and emotional state in vitiligo in an Estonian sample: comparison with psoriasis and healthy controls. Acta Derm Venereol 2013;93:446-450.
30.
Finlay AY, Khan G: Dermatology Life Quality Index (DLQI). A simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
31.
Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY: The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008;159:997-1035.
32.
Vrijman C, Homan ML, Limpens J, van der Veen W, Wolkerstorfer A, Terwee CB, Spuls PI: Measurement properties of outcome measures for vitiligo: a systematic review. Arch Dermatol 2012;148:1302-1309.
33.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY: Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005;125:659-664.
34.
Ingordo V, Cazzaniga S, Raone B, Digiuseppe MD, Musumeci ML, Fai D, Pellegrino M, Pezzarossa E, Di Lernia V, Battarra VC, Sirna R, Patrizi A, Naldi L: Circulating autoantibodies and autoimmune comorbidities in vitiligo patients: a multicenter Italian study. Dermatology 2014;228:240-249.
35.
Sampogna F, Picardi A, Chren MM, Melchi CF, Pasquini P, Masini C, Abeni D: Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 2004;66:620-624.
36.
Sampogna F, Raskovic D, Guerra L, Pedicelli C, Tabolli S, Leoni L, Alessandroni L, Abeni D: Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol 2008;159:351-359.
37.
Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R: Psychiatric morbidity in vitiligo: prevalence and correlates in India. J Eur Acad Dermatol Venereol 2002;16:573-578.
38.
Sampogna F: Life course impairment and quality of life over time. Curr Probl Dermatol 2013;44:47-51.
39.
Krüger C, Schallreuter KU: Cumulative life course impairment in vitiligo. Curr Probl Dermatol 2013;44:102-117.
40.
Harlow D, Poyner T, Finlay AY, Dykes PJ: Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000;143:979-982.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.